{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T22:10:25Z","timestamp":1778191825802,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018950","name":"Centre Hospitalier Universitaire de Rennes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.biopha.2021.112053","type":"journal-article","created":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:46:31Z","timestamp":1629333991000},"page":"112053","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Development of a dosing-adjustment tool for fluoroquinolones in osteoarticular infections: The Fluo-pop study"],"prefix":"10.1016","volume":"142","author":[{"given":"Florian","family":"Lemaitre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabien","family":"Fily","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Baptiste","family":"Foulquier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthieu","family":"Revest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Jullien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Petitcollin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Tattevin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Tron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Louis","family":"Polard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Cl\u00e9mence","family":"Verdier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Comets","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Huten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9dric","family":"Arvieux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Bellissant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Laviolle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2021.112053_bib1","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/jama.279.19.1537","article-title":"Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group","volume":"279","author":"Zimmerli","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2021.112053_bib2","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/cid\/cir402","article-title":"Outcome and predictors of treatment failure in total hip\/knee prosthetic joint infections due to Staphylococcus aureus","volume":"53","author":"Senneville","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.biopha.2021.112053_bib3","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.medmal.2009.05.004","volume":"39","author":"la Soci\u00e9t\u00e9 de Pathologie Infectieuse de Langue Fran\u00e7aise (SPILF)","year":"2009","journal-title":"Med Mal. Infect."},{"key":"10.1016\/j.biopha.2021.112053_bib4","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1128\/AAC.37.5.1073","article-title":"Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients","volume":"37","author":"Forrest","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2021.112053_bib5","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1086\/383320","article-title":"Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia","volume":"189","author":"Drusano","year":"2004","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.biopha.2021.112053_bib6","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1128\/AAC.49.7.2642-2647.2005","article-title":"Antistaphylococcal effect related to the area under the curve\/MIC ratio in an in vitro dynamic model: predicted breakpoints versus clinically achievable values for seven fluoroquinolones","volume":"49","author":"Firsov","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2021.112053_bib7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1128\/AAC.42.3.521","article-title":"Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy","volume":"42","author":"Thomas","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2021.112053_bib8","unstructured":"Soci\u00e9t\u00e9 de Pathologie Infectieuse de Langue Fran\u00e7aise (SPILF). Recommandations de pratique clinique Infections ost\u00e9o-articulaires sur mat\u00e9riel (proth\u00e8se, implant, ost\u00e9osynth\u00e8se) [Internet]. 2008 [cited 2020 Dec 28]. Available from: https:\/\/www.infectiologie.com\/UserFiles\/File\/medias\/_documents\/consensus\/inf-osseuse-court.pdf."},{"key":"10.1016\/j.biopha.2021.112053_bib9","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Recommandation de bonne pratique Proth\u00e8se de hanche ou de genou: diagnostic et prise en charge de l\u2019infection dans le mois suivant l\u2019implantation [Internet]. 2014 [cited 2020 Dec 28]. Available from: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2014\u201303\/rbp_recommandations_protheses_infectees_vd.pdf."},{"key":"10.1016\/j.biopha.2021.112053_bib10","unstructured":"The Comprehensive R Archive Network. ncappc: NCA Calculations and Population Model Diagnosis [Internet]. 2018 [cited 2020 Dec 28]. Available from: https:\/\/cran.r-project.org\/web\/packages\/ncappc\/index.html."},{"key":"10.1016\/j.biopha.2021.112053_bib11","series-title":"Mixed Effects Models for the Population Approach: Models, Tasks, Methods and Tools","author":"Lavielle","year":"2014"},{"key":"10.1016\/j.biopha.2021.112053_bib12","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1179\/joc.2007.19.6.682","article-title":"Penetration of moxifloxacin and levofloxacin into cancellous and cortical bone in patients undergoing total hip arthroplasty","volume":"19","author":"Metallidis","year":"2007","journal-title":"J. Chemother."},{"key":"10.1016\/j.biopha.2021.112053_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01092-18","article-title":"Population pharmacokinetic model and limited sampling strategies for personalized dosing of levofloxacin in tuberculosis patients","volume":"62","author":"van den Elsen","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2021.112053_bib14","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1128\/AAC.00048-12","article-title":"Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosis","volume":"56","author":"Chigutsa","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2021.112053_bib15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s10156-009-0714-8","article-title":"Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China","volume":"15","author":"Zhang","year":"2009","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.biopha.2021.112053_bib16","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1128\/AAC.01036-07","article-title":"Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis","volume":"52","author":"Peloquin","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2021.112053_bib17","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1128\/AAC.46.2.586-589.2002","article-title":"Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and monte carlo simulation","volume":"46","author":"Drusano","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2021.112053_bib18","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/cpdd.418","article-title":"Population pharmacokinetics of levofloxacin in plasma and bone of patients undergoing hip or knee surgery","volume":"7","author":"Gergs","year":"2018","journal-title":"Clin. Pharm. Drug Dev."},{"key":"10.1016\/j.biopha.2021.112053_bib19","article-title":"Influence of renal function and age on the pharmacokinetics of levofloxacin in patients with bone and joint infections","volume":"9","author":"Eloy","year":"2020","journal-title":"Antibiot. (Basel)"},{"key":"10.1016\/j.biopha.2021.112053_bib20","doi-asserted-by":"crossref","first-page":"503","DOI":"10.5588\/09640569513011","article-title":"Ofloxacin population pharmacokinetics in patients with tuberculosis","volume":"6","author":"Stambaugh","year":"2002","journal-title":"Int. J. Tube Lung Dis."},{"key":"10.1016\/j.biopha.2021.112053_bib21","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1179\/1973947815Y.0000000033","article-title":"Population pharmacokinetics of levofloxacin in Korean patients","volume":"28","author":"Kiem","year":"2016","journal-title":"J. Chemother."},{"key":"10.1016\/j.biopha.2021.112053_bib22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/00003088-200948020-00002","article-title":"Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations","volume":"48","author":"Landersdorfer","year":"2009","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.biopha.2021.112053_bib23","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0924-8579(01)00423-X","article-title":"Tissue and serum concentrations of levofloxacin in orthopaedic patients","volume":"18","author":"von Baum","year":"2001","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.biopha.2021.112053_bib24","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/jac\/dkh110","article-title":"Diffusion of levofloxacin into bone and synovial tissues","volume":"53","author":"Rimmel\u00e9","year":"2004","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221008362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221008362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:38:12Z","timestamp":1760099892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332221008362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":24,"alternative-id":["S0753332221008362"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112053","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a dosing-adjustment tool for fluoroquinolones in osteoarticular infections: The Fluo-pop study","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112053"}}